Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rapidly progressive glomerulonephritis with D-penicillamine.

Y Nanke1, H Akama, C Terai

  • 1Institute of Rheumatology, Tokyo Women's Medical University, Japan. ynn@ior.twmu.ac.jp

The American Journal of the Medical Sciences
|January 10, 2001
PubMed
Summary

D-penicillamine (D-PC) treatment for rheumatoid arthritis can trigger anti-neutrophil cytoplasmic antibody (ANCA)-associated rapidly progressive glomerulonephritis. Prompt immunosuppressive therapy improved renal function and resolved MPO-ANCA positivity in these cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update.

Clinical pharmacology and therapeutics·2015
Same author

High-accuracy imputation for HLA class I and II genes based on high-resolution SNP data of population-specific references.

The pharmacogenomics journal·2015
Same author

Lymphocyte dysfunction caused by deficiencies in purine metabolism.

Immunology today·2014
Same author

A huge congenital arachnoid cyst in a rheumatoid arthritis patient.

Modern rheumatology·2014
Same author

Renal function estimated from serum creatinine is overestimated in patients with rheumatoid arthritis because of their muscle atrophy.

Modern rheumatology·2014
Same author

Multicenter cooperative study of HLA class II alleles in Japanese patients with systemic lupus erythematosus.

Modern rheumatology·2014

Area of Science:

  • Nephrology
  • Rheumatology
  • Immunology

Background:

  • Rheumatoid arthritis (RA) is a chronic autoimmune disease.
  • D-penicillamine (D-PC) is a chelating agent used to treat RA.
  • Drug-induced kidney injury is a significant concern in RA treatment.

Observation:

  • Three RA patients developed rapidly progressive glomerulonephritis (RPGN) during D-PC therapy.
  • Patients presented with proteinuria, hematuria, renal insufficiency, and anemia.
  • High levels of anti-myeloperoxidase (MPO)-ANCA were detected in all patients.

Findings:

  • Renal biopsy revealed glomerulonephritis with cellular crescents and immune deposits (IgG, IgM, IgA, C1q, C3).
  • Discontinuation of D-PC was followed by immunosuppressive treatment (steroids, anticoagulants, cyclophosphamide).

Related Experiment Videos

  • Patients showed gradual improvement in renal function and MPO-ANCA seronegativity post-treatment.

    • Implications:

    • D-penicillamine can induce MPO-ANCA-positive RPGN in rheumatoid arthritis patients.
    • Early diagnosis and immunosuppressive treatment are crucial for managing D-PC-induced glomerulonephritis.
    • This highlights the importance of monitoring renal function in patients treated with D-PC.